News|Articles|December 9, 2024
NGS-Based Viral Safety Testing for ATMPs: Mandatory or Just an Option?
Author(s)Charles River
NGS-Based Viral Safety Testing for ATMPs: Mandatory or Just an Option?
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
CDC Revises Childhood Immunization Schedule, Shifting Demand Dynamics
2
New AI Oncology Alliance Highlights Industry Push for Scalable Genomics
3
Industry Outlook 2026: Biopharma Braces for Economic Upheaval While Eyeing AI-Driven Transformation (Part 1)
4
What Are the Benefits of Single-Use in CGT Manufacturing?
5